CYP2D6 polymorphisms influence tamoxifen treatment outcomes in

JPM, Free Full-Text

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population, Egyptian Journal of Medical Human Genetics

Pharmacogenetics and Psychiatric Care: A Review and Commentary

PDF] Pharmacogenomics of tamoxifen therapy.

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial - ScienceDirect

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? - ScienceDirect

Full article: CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives - ScienceDirect

Does CYP2D6 Genotyping have a Role in Guiding Tamoxifen Therapy?

Frontiers Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis